Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management

Lancet. 2022 Jan 1;399(10319):21-22. doi: 10.1016/S0140-6736(21)02657-X.

Authors

Joseph Heskin¹, Scott J C Pallett², Nabeela Mughal³, Gary W Davies³, Luke S P Moore³, Michael Rayment³, Rachael Jones³

Affiliations

¹ Chelsea and Westminster Hospital NHS Foundation Trust, London SW10 9NH, UK. Electronic address: j.heskin@nhs.net.
² Royal Defence Medical College, Royal Centre for Defence Medicine, Birmingham, UK.
³ Chelsea and Westminster Hospital NHS Foundation Trust, London SW10 9NH, UK.

No abstract available

Publication types

Letter

MeSH terms

COVID-19 Drug Treatment*
Drug Interactions
Drug Therapy, Combination
Humans
Lactams / therapeutic use*
Leucine / therapeutic use*
Nitriles / therapeutic use*
Proline / therapeutic use*
Ritonavir / adverse effects*
Ritonavir / pharmacokinetics
Ritonavir / pharmacology
Ritonavir / therapeutic use*
Viral Protease Inhibitors* / adverse effects
Viral Protease Inhibitors* / pharmacokinetics
Viral Protease Inhibitors* / therapeutic use

Substances

Lactams
Nitriles
Viral Protease Inhibitors
nirmatrelvir
Proline
Leucine
Ritonavir